Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

South Korea-based developer of RNAi therapeutics developer OliX Pharmaceuticals has announced a global licensing agreement with Eli Lilly.

What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.

Sleep-apnoea-tackling Resmed is dreaming big but the question is: what can upset the Aussie biotech's growth story?

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

Targeting CB1 receptors is not a new concept in the biotech and pharma worlds ... and in combination with Eli Lilly's (LLY) Zepbound (tirzepatide). Scholar Rock (NASDAQ:SRRK) CEO Jay Backstrom ...

With Robert F. Kennedy Jr. set to be sworn in as HHS secretary later Thursday, one of the first tasks in his new position will be to implement some of the ideas spelled out in his "Make America Health ...

The proposal, unveiled at the government's International Investment Summit today is headlined by the creation of a UK biotech hub ... evidence study involving tirzepatide, the dual GIP/GLP ...

A small semaglutide trial suggests the medicine's suppression of appetite may extend to alcohol, but larger tests are needed ...